首页> 外文期刊>Pediatric Research >Effect of Single and Multiple Courses of Prenatal Corticosteroids on 17-Hydroxyprogesterone Levels: Implication for Neonatal Screening of Congenital Adrenal Hyperplasia
【24h】

Effect of Single and Multiple Courses of Prenatal Corticosteroids on 17-Hydroxyprogesterone Levels: Implication for Neonatal Screening of Congenital Adrenal Hyperplasia

机译:产前皮质类固醇单次和多次疗程对17-羟孕酮水平的影响:对先天性肾上腺皮质增生的新生儿筛查的意义

获取原文
获取外文期刊封面目录资料

摘要

Measurement of 17-hydroxyprogesterone (17-OHP) from filter-paper blood is widely used to screen for congenital adrenal hyperplasia (CAH). However, in pregnancies with an expected preterm delivery, prenatal treatment with steroids to induce pulmonary maturation could suppress the fetal adrenals and interfere with this screening. In 160 infants who were born between 25 and 35 wk of gestation, we measured 17-OHP in filter-paper blood at 72–96 h and compared the values between those who had not received antenatal steroids (n = 50) and those who had (n = 110). A single course of steroids was two 12-mg injections of betamethasone given within a 24-h interval: 30 infants received a half single course, 45 received a full single course, and 35 received multiple courses. Results are expressed as medians (25th percentile; 75th percentile). Blood 17-OHP differed significantly among groups: 23.7 (14.2; 30.7) nmol/L, 26.1 (15.0; 50.1) nmol/L, 20.1 (13.8; 29.1) nmol/L, and 14.9 (9.5; 26.2) nmol/L (for, respectively, no steroid, half a single course, a full single course, and multiple courses; p p U test). In multiple regression analysis, steroid treatment and intrauterine growth retardation were significant negative predictors of blood 17-OHP, whereas respiratory distress syndrome was a significant positive predictor (multiple R = 0.50, p Abbreviations: CAH, congenital adrenal hyperplasia; IUGR, intrauterine growth retardation; RDS, respiratory distress syndrome; 17-OHP, 17-hydroxyprogesterone
机译:从滤纸血液中检测17-羟基孕酮(17-OHP)已广泛用于筛查先天性肾上腺皮质增生(CAH)。但是,在预期早产的孕妇中,用类固醇诱导肺成熟的产前治疗可能会抑制胎儿肾上腺并干扰这种筛查。在160名出生于妊娠25至35周之间的婴儿中,我们在72-96 h时测量了滤纸血液中的17-OHP,并比较了未接受产前类固醇(n = 50)和未接受过激素治疗的婴儿中的值。 (n = 110)。单剂类固醇是在24小时间隔内两次注射倍他米松12 mg:30例婴儿接受半个疗程,45例接受一个完整疗程,35例接受多个疗程。结果以中位数(25%; 75%)表示。各组之间的血液17-OHP差异显着:23.7(14.2; 30.7)nmol / L,26.1(15.0; 50.1)nmol / L,20.1(13.8; 29.1)nmol / L和14.9(9.5; 26.2)nmol / L(分别为无类固醇,半单课程,全单课程和多课程; pp U测试)。在多元回归分析中,类固醇治疗和宫内发育迟缓是血液17-OHP的显着阴性指标,而呼吸窘迫综合征是血液中17-OHP的显着阳性指标(多重R = 0.50,p缩写:CAH,先天性肾上腺增生; IUGR,宫内生长迟缓; RDS,呼吸窘迫综合征; 17-OHP,17-羟基孕酮

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号